A Phase 3 interventional study of Leuprolide acetate 11.25 mg and Leuprolide acetate 30 mg in Puberty, Precocious, sponsored by Abbott. Completed at 25 sites in 2 countries. Open to participants aged 2 Years to 11 Years. Per ClinicalTrials.gov, last updated 2011-11-02.
Sponsored by Abbott · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.
Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 5th largest by enrollment, is one of 2 that started in 2008, is one of 6 in phase 3, and was the 1st registered.
75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.
Browse Puberty, Precocious studies →2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:
LG Chem · Sites in Korea, Republic of
Ages up to 10
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 4–10
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.
This study: 2 Years to 11 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 1991; this study’s year is marked. 2 started in 2008.
This study's enrollment of 84 is above the median of 64 across 47 interventional studies indexed under Puberty, Precocious.
Median enrollment 68 across the 14 interventional studies. Of the 9 that completed or were terminated, 6 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 14 have an industry lead sponsor. The 10 most frequent:
Abbott is the lead sponsor of 361 studies on the registry; 1 is open to participants now.
Abbott has 2 studies filed under Puberty, Precocious — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing leuprolide in Puberty, Precocious, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine if 11.25 and 30 mg formulations of leuprolide are effective in treating children with Central Precocious Puberty (CPP).
Study Design:
A total of 80 children with confirmed CPP were planned to be enrolled and randomized in a 1:1 ratio to receive 2 injections of either leuprolide acetate 11.25 mg or 30 mg depot formulation, each injection administered 3 mo apart (6 mo of treatment):
This study includes a 4-week Screening Period, two 3-mo treatment cycles, and a posttreatment follow-up period (12 weeks following the Mo 6 visit). Study visits will occur at Screening, Day 1, Week 2 (only for subjects participating in the pharmacokinetic subset), Mo 1, 2, 3, Mo 6/Early Termination, and 12 weeks later, for the Posttreatment Follow-up Visit.
This study was conducted at 18 sites in the United States and 4 sites in Puerto Rico.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Additional criteria for subjects who have not had previous treatment:
Additional criteria for subjects previously treated:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
There are 2 arms that received leuprolide acetate 11.25 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm A and subjects who have previously been treated with leuprolide acetate are designated to be in Arm B.
Drug: Leuprolide acetate 11.25 mg
There are 2 arms that received leuprolide acetate 30 mg. Subjects who are treatment naive to leuprolide acetate are designated to be in Arm C and subjects who have previously been treated with leuprolide acetate are designated to be in Arm D.
Drug: Leuprolide acetate 30 mg
Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
Also known as: ABT-818, leuprolide acetate, Lupron
Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
Also known as: ABT-818, leuprolide acetate, Lupron
Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6
Percentage of participants with suppression of peak stimulated luteinizing hormone that was measured after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test at Month (Mo) 2, 3, and 6. The analysis was performed according to a life table method. Subjects who withdrew without peak-stimulated luteinizing hormone \>= 4 mIU/mL were censored at their last measurement of peak-stimulated luteinizing hormone.
Time frame: Month 2 through 6
Percentage of Participants With Suppression of Basal Estradiol <20 pg/mL by Visit
Percentage of participants with suppression of estradiol, out of the number of girls with at least 1 estradiol measurement at each visit (n/N%). Only girls are analyzed in this outcome measure. Observed data were used with no imputation for missing data.
Time frame: Month 1, 2, 3 and 6
Percentage of Participants With Suppression of Testosterone in <30 ng/dL by Visit
Percentage of participants with suppression of testosterone, out of the number of boys with at least 1 testosterone measurement at each visit (n/N%). Only boys are analyzed in this outcome measure. Observed data were used with no imputation for missing data.
Time frame: Month 1, 2, 3 and 6
Peak-stimulated Luteinizing Hormone Concentration by Visit
Observed data were used with no imputation for missing data.
Time frame: Baseline, Month 1, 2, 3 and 6
Percentage of Participants With Suppression of the Physical Signs of Puberty (Breast Development) at Month 6
Percentage of participants with suppression of breast development, out of the number of girls with pubertal staging of breast development (n/N%). Only girls are analyzed in this outcome measure. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a Tanner Staging pictogram. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Observed data were used with no imputation for missing data.
Time frame: Month 6
Percentage of Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development) at Month 6
Percentage of participants with suppression of genital development and testicular volume, out of the number of boys with pubertal staging of genital development or testicular volume (n/N%). Only boys are analyzed in this outcome measure. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a Tanner Staging pictogram. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Observed data were used with no imputation for missing data.
Time frame: Month 6
Change From Baseline in Incremental Growth Rate (cm/Year) at Month 6
The growth rate at baseline was the growth rate during the last year before the start of treatment and was calculated with the measurement closest to Day -336 (before Day -30) and the measurement up to Day 1. Growth rate at Month 6 was defined as the ratio of the change in height from Day 1 to the change in chronological age, with an approximate 6-month interval between the 2 height measurements. Observed data were used with no imputation for missing data.
Time frame: Baseline and Month 6
Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age at Month 6
The ratio at Month 6 was calculated as (bone age at Month 6 - bone age at baseline)/(chronological age at Month 6 - chronological age at baseline). Observed data were used with no imputation for missing data. Baseline bone-age radiograph was performed at or within 3 months of the Screening Visit.
Time frame: Baseline to Month 6
Eighteen sites in the US and 4 sites in Puerto Rico enrolled subjects into the study. The first subject was randomized 17 June 2008 and the last subject was randomized 12 Aug 2009.
| Milestone | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Started | 21 | 21 | 21 | 21 |
| Completed | 15 | 19 | 19 | 21 |
| Not completed | 6 | 2 | 2 | 0 |
Percentage of participants with suppression of peak stimulated luteinizing hormone that was measured after a gonadotropin-releasing hormone agonist (GnRHa) stimulation test at Month (Mo) 2, 3, and 6. The analysis was performed according to a life table method. Subjects who withdrew without peak-stimulated luteinizing hormone \>= 4 mIU/mL were censored at their last measurement of peak-stimulated luteinizing hormone.
| Percentage of Participants | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6 | 76.2 ± 9.29 | 80.7 ± 8.69 | 90.5 ± 6.41 | 100 ± 0.00 |
Percentage of participants with suppression of estradiol, out of the number of girls with at least 1 estradiol measurement at each visit (n/N%). Only girls are analyzed in this outcome measure. Observed data were used with no imputation for missing data.
| Percentage of Participants | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Mo 1 (Arm A N=17, B N=18, C N=19, D N=16) | 100 (80.5 to 100) | 100 (81.5 to 100) | 100 (82.4 to 100) | 100 (79.4 to 100) |
| Mo 2 (Arm A N=19, B N=14, C N=19, D N=14) | 94.7 (74.0 to 99.9) | 100 (76.8 to 100) | 100 (82.4 to 100) | 100 (76.8 to 100) |
| Mo 3 (Arm A N=15, B N=18, C N=17, D N=18) | 100 (78.2 to 100) | 100 (81.5 to 100) | 100 (80.5 to 100) | 100 (81.5 to 100) |
| Mo 6 (Arm A N=12, B N=16, C N=15, D N=17) | 100 (73.5 to 100) | 93.8 (69.8 to 99.8) | 100 (78.2 to 100) | 100 (80.5 to 100) |
Percentage of participants with suppression of testosterone, out of the number of boys with at least 1 testosterone measurement at each visit (n/N%). Only boys are analyzed in this outcome measure. Observed data were used with no imputation for missing data.
| Percentage of Participants | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Mo 1 (Arm A N=2, B N=1, C N=2, D N=3) | 50.0 (1.3 to 98.7) | 100 (2.5 to 100) | 100 (15.8 to 100) | 100 (29.2 to 100) |
| Mo 2 (Arm A N=2, B N=1, C N=2, D N=3) | 50.0 (1.3 to 98.7) | 100 (2.5 to 100) | 100 (15.8 to 100) | 100 (29.2 to 100) |
| Mo 3 (Arm A N=2, B N=1, C N=2, D N=3) | 50.0 (1.3 to 98.7) | 100 (2.5 to 100) | 100 (15.8 to 100) | 100 (29.2 to 100) |
| Mo 6 (Arm A N=1, B N=1, C N=2, D N=3) | 100 (2.5 to 100) | 100 (2.5 to 100) | 100 (15.8 to 100) | 100 (29.2 to 100) |
Observed data were used with no imputation for missing data.
| mIU/mL | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Baseline (Arm A N=21, B N=21, C N=21, D N=21) | 45.9 ± 42.38 | 1.8 ± 1.78 | 23.5 ± 16.76 | 1.7 ± 1.09 |
| Mo 1 (Arm A N=21, B N=21, C N=21, D N=21) | 4.4 ± 7.29 | 1.7 ± 1.36 | 1.9 ± 1.74 | 1.4 ± 0.76 |
| Mo 2 (Arm A N=21, B N=20, C N=21, D N=20) | 4.5 ± 7.20 | 2.0 ± 1.48 | 2.0 ± 2.25 | 1.5 ± 0.73 |
| Mo 3 (Arm A N=16, B N=20, C N=20, D N=21) | 2.3 ± 1.23 | 1.8 ± 1.10 | 1.4 ± 0.78 | 1.5 ± 0.61 |
| Mo 6 (Arm A N=15, B N=18, C N=18, D N=21) | 2.0 ± 0.85 | 2.5 ± 2.43 | 1.6 ± 0.95 | 1.5 ± 0.89 |
Percentage of participants with suppression of breast development, out of the number of girls with pubertal staging of breast development (n/N%). Only girls are analyzed in this outcome measure. Breast development was rated from Stage 1 (early development) through Stage 5 (full development) according to a Tanner Staging pictogram. Girls entering the study with fully developed breasts (Stage 5) were excluded from this analysis. Observed data were used with no imputation for missing data.
| Percentage of Participants | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Percentage of Participants With Suppression of the Physical Signs of Puberty (Breast Development) at Month 6 | 92.9 (66.1 to 99.8) | 88.9 (65.3 to 98.6) | 82.4 (56.6 to 96.2) | 82.4 (56.6 to 96.2) |
Percentage of participants with suppression of genital development and testicular volume, out of the number of boys with pubertal staging of genital development or testicular volume (n/N%). Only boys are analyzed in this outcome measure. External genital development (testes and penis) was rated from Stage 1 (early development) through Stage 5 (full development) according to a Tanner Staging pictogram. Boys entering the study with fully developed genitals (Stage 5) were excluded from this analysis. Observed data were used with no imputation for missing data.
| Percentage of Participants | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Percentage of Participants With Suppression of the Physical Signs of Puberty (Testicular Volume and Genital Development) at Month 6 | 100 (2.5 to 100) | 0 (0.0 to 97.5) | 50 (1.3 to 98.7) | 33.3 (0.8 to 90.6) |
The growth rate at baseline was the growth rate during the last year before the start of treatment and was calculated with the measurement closest to Day -336 (before Day -30) and the measurement up to Day 1. Growth rate at Month 6 was defined as the ratio of the change in height from Day 1 to the change in chronological age, with an approximate 6-month interval between the 2 height measurements. Observed data were used with no imputation for missing data.
| cm/year | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Baseline (Arm A N=20, B N=21, C N=21, D N=21) | 7.25 ± 5.30 | 6.58 ± 2.39 | 7.83 ± 5.96 | 6.05 ± 1.55 |
| Mo 6 (Arm A N=14, B N=19, C N=19, D N=21) | -2.51 ± 5.29 | -0.98 ± 2.24 | -2.34 ± 4.22 | -0.91 ± 2.45 |
The ratio at Month 6 was calculated as (bone age at Month 6 - bone age at baseline)/(chronological age at Month 6 - chronological age at baseline). Observed data were used with no imputation for missing data. Baseline bone-age radiograph was performed at or within 3 months of the Screening Visit.
| Ratio | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Ratio of Change From Baseline in Bone Age/Change From Baseline in Chronological Age at Month 6 | 0.59 ± 0.59 | 0.50 ± 0.57 | 1.00 ± 0.74 | 1.07 ± 1.60 |
Percentage of participants with suppression of peak stimulated luteinizing hormone that was measured after a GnRHa stimulation test at Mo 2, 3, and 6. A simple percentage and binomial exact confidence intervals were used in this analysis. Participants who withdrew with luteinizing hormone that remained suppressed were counted as a success. This analysis was performed after the clinical study report was completed and is included to match the FDA package insert.
| Percentage of Participants | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (< 4 mIU/mL) From Month 2 Through Month 6 (Simple Percentage With Binomial Exact Confidence Intervals) | 76.2 (52.8 to 91.8) | 81.0 (58.1 to 94.6) | 90.5 (69.6 to 98.8) | 100.0 (83.9 to 100.0) |
The ratio at baseline or Month 6 was calculated as bone age at baseline or Month 6/chronological age at baseline or Month 6. The percentage of participants with a decrease in the ratio was calculated as a simple percentage for each dose group. Observed data were used with no imputation for missing data. The baseline time frame was increased from the secondary outcome in this analysis to include all participants with a bone age radiograph at screening. This analysis was performed after the clinical study report was completed \& is included to match the FDA package insert.
| Percentage of Participants | Leuprolide Acetate 11.25 mg | Leuprolide Acetate 30 mg |
|---|---|---|
| Percentage of Participants With a Decrease From Baseline in the Ratio of Bone Age to Chronological Age at Month 6 Compared to Baseline | 87.9 | 75.0 |
Collected over Treatment-emergent adverse events were defined as any event with an onset data after the first dose of study drug and with an onset date no more than 30 days after the last day of study drug treatment which is 84 days after the last injection date.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leuprolide Acetate 11.25 mg - Treatment Naive | — | 1/21 (4.8%) | 13/21 (61.9%) |
| Leuprolide Acetate 11.25 mg - Previous Treatment | — | 0/21 (0%) | 18/21 (85.7%) |
| Leuprolide Acetate 30 mg - Treatment Naive | — | 0/21 (0%) | 15/21 (71.4%) |
| Leuprolide Acetate 30 mg - Previous Treatment | — | 1/21 (4.8%) | 17/21 (81%) |
| Event | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| DepressionPsychiatric disorders | 1/21 | 0/21 | 0/21 | 0/21 |
| NauseaGastrointestinal disorders | 0/21 | 0/21 | 0/21 | 1/21 |
| Weight DecreasedGastrointestinal disorders | 0/21 | 0/21 | 0/21 | 1/21 |
| VomitingGastrointestinal disorders | 0/21 | 0/21 | 0/21 | 1/21 |
| DiarrheaGastrointestinal disorders | 0/21 | 0/21 | 0/21 | 1/21 |
| Event | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment |
|---|---|---|---|---|
| Injection Site PainGeneral disorders | 4/21 | 4/21 | 4/21 | 7/21 |
| PyrexiaGeneral disorders | 2/21 | 2/21 | 2/21 | 6/21 |
| HeadacheNervous system disorders | 1/21 | 4/21 | 6/21 | 6/21 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/21 | 4/21 | 2/21 | 5/21 |
| VomitingGastrointestinal disorders | 0/21 | 1/21 | 4/21 | 1/21 |
| NasopharyngitisInfections and infestations | 1/21 | 4/21 | 1/21 | 1/21 |
| Nasal congestionRespiratory, thoracic and mediastinal disorders | 3/21 | 1/21 | 4/21 | 1/21 |
| Upper Respiratory Tract InfectionInfections and infestations | 2/21 | 3/21 | 3/21 | 2/21 |
| Respiratory DisordersRespiratory, thoracic and mediastinal disorders | 0/21 | 3/21 | 0/21 | 0/21 |
| RhinorrheaRespiratory, thoracic and mediastinal disorders | 1/21 | 0/21 | 0/21 | 3/21 |
| Age, Categorical(Participants) | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment | Total |
|---|---|---|---|---|---|
| <=18 years | 21 | 21 | 21 | 21 | 84 |
| Between 18 and 65 years | 0 | 0 | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Age Continuous(Years) | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment | Total |
|---|---|---|---|---|---|
| Mean | 7.4 ± 1.47 | 8.1 ± 1.83 | 7.3 ± 1.74 | 8.4 ± 1.75 | 7.8 ± 1.73 |
| Sex: Female, Male(Participants) | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment | Total |
|---|---|---|---|---|---|
| Female | 19 | 20 | 19 | 18 | 76 |
| Male | 2 | 1 | 2 | 3 | 8 |
| Region of Enrollment(Participants) | Leuprolide Acetate 11.25 mg - Treatment Naive | Leuprolide Acetate 11.25 mg - Previous Treatment | Leuprolide Acetate 30 mg - Treatment Naive | Leuprolide Acetate 30 mg - Previous Treatment | Total |
|---|---|---|---|---|---|
| North America | 21 | 21 | 21 | 21 | 84 |
The record gives a start of Jun 2008, a primary completion of Jan 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide